CGEN Quote, Financials, Valuation and Earnings

Can Fite Biofarma has a net margin of 7.45% compared to Compugen's net margin of --. Compugen's return on equity of 2.69% beat Can Fite Biofarma's return on equity of --.

Compugen has a consensus price target of --, signalling upside risk potential of 150%. On the other hand Can Fite Biofarma has an analysts' consensus of -- which suggests that it could grow by 879.02%. Given that Can Fite Biofarma has higher upside potential than Compugen, analysts believe Can Fite Biofarma is more attractive than Compugen.

Compugen has a beta of 2.588, which suggesting that the stock is 158.818% more volatile than S&P 500. In comparison Can Fite Biofarma has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.764%.

Compugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can Fite Biofarma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen pays -- of its earnings as a dividend. Can Fite Biofarma pays out -- of its earnings as a dividend.

Compugen quarterly revenues are $17.1M, which are larger than Can Fite Biofarma quarterly revenues of --. Compugen's net income of $1.3M is higher than Can Fite Biofarma's net income of --. Notably, Compugen's price-to-earnings ratio is 53.33x while Can Fite Biofarma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen is 2.39x versus 13.42x for Can Fite Biofarma. Usually stocks with elevated PS ratios are considered overvalued.

BiomX has a net margin of 7.45% compared to Compugen's net margin of --. Compugen's return on equity of 2.69% beat BiomX's return on equity of --.

Compugen has a consensus price target of --, signalling upside risk potential of 150%. On the other hand BiomX has an analysts' consensus of -- which suggests that it could grow by 1187.48%. Given that BiomX has higher upside potential than Compugen, analysts believe BiomX is more attractive than Compugen.

Compugen has a beta of 2.588, which suggesting that the stock is 158.818% more volatile than S&P 500. In comparison BiomX has a beta of 1.314, suggesting its more volatile than the S&P 500 by 31.404%.

Compugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen pays -- of its earnings as a dividend. BiomX pays out -- of its earnings as a dividend.

Compugen quarterly revenues are $17.1M, which are larger than BiomX quarterly revenues of --. Compugen's net income of $1.3M is lower than BiomX's net income of $9.6M. Notably, Compugen's price-to-earnings ratio is 53.33x while BiomX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen is 2.39x versus -- for BiomX. Usually stocks with elevated PS ratios are considered overvalued.

Pluri has a net margin of 7.45% compared to Compugen's net margin of -1804.3%. Compugen's return on equity of 2.69% beat Pluri's return on equity of -438.78%.

Compugen has a consensus price target of --, signalling upside risk potential of 150%. On the other hand Pluri has an analysts' consensus of -- which suggests that it could grow by 619.1%. Given that Pluri has higher upside potential than Compugen, analysts believe Pluri is more attractive than Compugen.

Compugen has a beta of 2.588, which suggesting that the stock is 158.818% more volatile than S&P 500. In comparison Pluri has a beta of 1.642, suggesting its more volatile than the S&P 500 by 64.245%.

Compugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen pays -- of its earnings as a dividend. Pluri pays out -- of its earnings as a dividend.

Compugen quarterly revenues are $17.1M, which are larger than Pluri quarterly revenues of $326K. Compugen's net income of $1.3M is higher than Pluri's net income of -$5.9M. Notably, Compugen's price-to-earnings ratio is 53.33x while Pluri's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen is 2.39x versus 39.53x for Pluri. Usually stocks with elevated PS ratios are considered overvalued.

XTL Biopharmaceuticals has a net margin of 7.45% compared to Compugen's net margin of --. Compugen's return on equity of 2.69% beat XTL Biopharmaceuticals's return on equity of --.

Compugen has a consensus price target of --, signalling upside risk potential of 150%. On the other hand XTL Biopharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 1495.75%. Given that XTL Biopharmaceuticals has higher upside potential than Compugen, analysts believe XTL Biopharmaceuticals is more attractive than Compugen.

Compugen has a beta of 2.588, which suggesting that the stock is 158.818% more volatile than S&P 500. In comparison XTL Biopharmaceuticals has a beta of 1.156, suggesting its more volatile than the S&P 500 by 15.571%.

Compugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XTL Biopharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compugen pays -- of its earnings as a dividend. XTL Biopharmaceuticals pays out -- of its earnings as a dividend.

Compugen quarterly revenues are $17.1M, which are larger than XTL Biopharmaceuticals quarterly revenues of --. Compugen's net income of $1.3M is higher than XTL Biopharmaceuticals's net income of $485K. Notably, Compugen's price-to-earnings ratio is 53.33x while XTL Biopharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compugen is 2.39x versus -- for XTL Biopharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.